Status:
ACTIVE_NOT_RECRUITING
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
Lead Sponsor:
Novartis
Conditions:
Essential Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
This study is a non-interventional, secondary use of data, retrospective, cohort study, and the data to be extracted in this study will be used as secondary use of collected patient information in the...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosed with essential hypertension (International Classification of Diseases \[ICD\]-10 code: I10) on the index date.
- Patients for whom data for the 6 months prior to the index date can be extracted as baseline data.
- Patients for whom blood pressure (BP) data can be extracted between weeks 8 and 12 after the index date.
- Patients whose BP data can be extracted on the index date.
- Patients whose BP value at baseline was 140/90 millimeters of mercury (mmHg) or higher.
- Patients with the prescription of 100 milligrams (mg) or 200 mg once daily as 100 mg or 200 mg tablets on the index date.
- Exclusion criteria:
- Women with a record of pregnancy-related diagnoses, drugs, or medical procedures before or after the index date, or a record of delivery- or abortion-related diagnoses, drugs, or medical procedures after the index date.
- Prescription of concomitant angiotensin-converting enzyme inhibitor (ACEi); Anatomical Therapeutic Chemical (ATC) code: C09A on, after, or in the 2 days before the index date.
- Patients diagnosed with angioedema: ICD-10: D84.1 under prescription of ACEi or angiotensin receptor blocker (ARB); ATC code: C09C.
- Patients diagnosed with diabetes and under treatment with aliskiren fumarate on the index date.
- Patients with severe impaired liver functions with Child-Pugh classification C.
Exclusion
Key Trial Info
Start Date :
January 31 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2025
Estimated Enrollment :
1405 Patients enrolled
Trial Details
Trial ID
NCT06604897
Start Date
January 31 2023
End Date
March 31 2025
Last Update
September 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
East Hanover, New Jersey, United States, 07936